Description
BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. BAY 57-1293 has been shown to be a more effective agent than acyclovir (Cat. No. 2200) for treating Alzjeimer’s Disease (AD) by decreasing Aβ and P-tau formation.
Peptide sequence
N/A
CAS number
348086-71-5
Molecular weight
402.49
Category
Biochemicals
Other name
N-methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide
Molecular formula
C₁₈H₁₈N₄O₃S₂
Physical appearance
White to off-white solid
Supplied with
N/A
Is this a salt?
No
Is it cell-permeable?
Yes
Purification
≥95% by HPLC
Reconstitute instructions
DMSO
Storage condition
-20°C
Shipping condition
Gel pack
Maximum time for storage
24 months
Storage instructions
Protect from air and light
Additional description
For cells, cell lines and tissues in culture till half confluency.
Gene targetBAY
57-1293
for
activation
Short name
BAY 57-1293 for activation
Technique
activation
Alternative name
BAY 57-1293 to measure cellular activation
Tissue
cell
